Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications
Cardiovascular disease (CVD), particularly atherosclerosis‐associated CVD, is a major cause of long‐term mortality after liver transplantation (LT). The liver is central in lipid homeostasis, and changes associated with insulin resistance, weight gain, adipose tissue inflammation, and development of...
Gespeichert in:
| Veröffentlicht in: | Liver transplantation 2021-09, Vol.27 (9), p.1326-1333 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1333 |
|---|---|
| container_issue | 9 |
| container_start_page | 1326 |
| container_title | Liver transplantation |
| container_volume | 27 |
| creator | Syed, Taseen Siddiqui, Mohammad S. |
| description | Cardiovascular disease (CVD), particularly atherosclerosis‐associated CVD, is a major cause of long‐term mortality after liver transplantation (LT). The liver is central in lipid homeostasis, and changes associated with insulin resistance, weight gain, adipose tissue inflammation, and development of nonalcoholic fatty liver disease (NAFLD) after LT promote atherogenesis. These factors synergistically alter lipid homeostasis, thereby leading to the production of proatherogenic lipoproteins, which contribute to the heighted risk of CVD‐associated events observed in LT recipients. Although the exact mechanism promoting this shift of a proatherogenic lipoprotein profile is currently not known, the choice of immunosuppression and preexisting metabolic risk factors (ie, NAFLD) are likely contributors. This shift in proatherogenic lipoprotein subparticles presents clinical challenges as the traditional lipid profile employed in clinical practice may not fully capture this atherogenic risk. This review focuses on lipoprotein metabolism and atherogenesis in LT recipients.
https://wileyhealthlearning.com/#/online-courses/ddb74a8d-493b-4e33-b8cc-820c79cff7cc |
| doi_str_mv | 10.1002/lt.26069 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2511237841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2511237841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3499-ffe0f9dbd3a2e02f6934a4a59a0d52a1f5022e3b4f9c81c9eec98fa591d3ba8b3</originalsourceid><addsrcrecordid>eNp1kE1Lw0AQhhdRbK2Cv0ACXryk7kc2yXor9atQ8VIvXsImmbVbNh_uJkr_vVtbKwheZgbmmYfhReic4DHBmF6bbkxjHIsDNCScJmEcJexwP8d8gE6cW2FMCBf4GA0YS1kSJ3iIXifdEmzzBrUugtu1M7rVJVRaBhPVgQ3m-sPXhZW1a42sO9nppr4JnqBYylq7ygWyLoOp0f5emmBWtcYPG8idoiMljYOzXR-hl_u7xfQxnD8_zKaTeViwSIhQKcBKlHnJJAVMVSxYJCPJhcQlp5IojikFlkdKFCkpBEAhUuX3pGS5THM2Qldbb2ub9x5cl1XaFWD8u9D0LqOcEMqSNCIevfyDrpre1v47TyU44pxw_CssbOOcBZW1VlfSrjOCs03ememy77w9erET9nkF5R78CdgD4Rb41AbW_4qy-WIr_AIFMYlp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2570455150</pqid></control><display><type>article</type><title>Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications</title><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Syed, Taseen ; Siddiqui, Mohammad S.</creator><creatorcontrib>Syed, Taseen ; Siddiqui, Mohammad S.</creatorcontrib><description>Cardiovascular disease (CVD), particularly atherosclerosis‐associated CVD, is a major cause of long‐term mortality after liver transplantation (LT). The liver is central in lipid homeostasis, and changes associated with insulin resistance, weight gain, adipose tissue inflammation, and development of nonalcoholic fatty liver disease (NAFLD) after LT promote atherogenesis. These factors synergistically alter lipid homeostasis, thereby leading to the production of proatherogenic lipoproteins, which contribute to the heighted risk of CVD‐associated events observed in LT recipients. Although the exact mechanism promoting this shift of a proatherogenic lipoprotein profile is currently not known, the choice of immunosuppression and preexisting metabolic risk factors (ie, NAFLD) are likely contributors. This shift in proatherogenic lipoprotein subparticles presents clinical challenges as the traditional lipid profile employed in clinical practice may not fully capture this atherogenic risk. This review focuses on lipoprotein metabolism and atherogenesis in LT recipients.
https://wileyhealthlearning.com/#/online-courses/ddb74a8d-493b-4e33-b8cc-820c79cff7cc</description><identifier>ISSN: 1527-6465</identifier><identifier>EISSN: 1527-6473</identifier><identifier>DOI: 10.1002/lt.26069</identifier><identifier>PMID: 33837670</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>Adipose tissue ; Arteriosclerosis ; Atherogenesis ; Cardiovascular diseases ; Dyslipidemia ; Fatty liver ; Homeostasis ; Immunosuppression ; Insulin ; Insulin resistance ; Lipid metabolism ; Lipids ; Lipoproteins ; Liver ; Liver diseases ; Liver transplantation ; Liver transplants ; Metabolic disorders ; Risk factors</subject><ispartof>Liver transplantation, 2021-09, Vol.27 (9), p.1326-1333</ispartof><rights>Copyright © 2021 by the American Association for the Study of Liver Diseases</rights><rights>This article is protected by copyright. All rights reserved.</rights><rights>2021 by the American Association for the Study of Liver Diseases.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3499-ffe0f9dbd3a2e02f6934a4a59a0d52a1f5022e3b4f9c81c9eec98fa591d3ba8b3</citedby><cites>FETCH-LOGICAL-c3499-ffe0f9dbd3a2e02f6934a4a59a0d52a1f5022e3b4f9c81c9eec98fa591d3ba8b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flt.26069$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flt.26069$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33837670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Syed, Taseen</creatorcontrib><creatorcontrib>Siddiqui, Mohammad S.</creatorcontrib><title>Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications</title><title>Liver transplantation</title><addtitle>Liver Transpl</addtitle><description>Cardiovascular disease (CVD), particularly atherosclerosis‐associated CVD, is a major cause of long‐term mortality after liver transplantation (LT). The liver is central in lipid homeostasis, and changes associated with insulin resistance, weight gain, adipose tissue inflammation, and development of nonalcoholic fatty liver disease (NAFLD) after LT promote atherogenesis. These factors synergistically alter lipid homeostasis, thereby leading to the production of proatherogenic lipoproteins, which contribute to the heighted risk of CVD‐associated events observed in LT recipients. Although the exact mechanism promoting this shift of a proatherogenic lipoprotein profile is currently not known, the choice of immunosuppression and preexisting metabolic risk factors (ie, NAFLD) are likely contributors. This shift in proatherogenic lipoprotein subparticles presents clinical challenges as the traditional lipid profile employed in clinical practice may not fully capture this atherogenic risk. This review focuses on lipoprotein metabolism and atherogenesis in LT recipients.
https://wileyhealthlearning.com/#/online-courses/ddb74a8d-493b-4e33-b8cc-820c79cff7cc</description><subject>Adipose tissue</subject><subject>Arteriosclerosis</subject><subject>Atherogenesis</subject><subject>Cardiovascular diseases</subject><subject>Dyslipidemia</subject><subject>Fatty liver</subject><subject>Homeostasis</subject><subject>Immunosuppression</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Lipid metabolism</subject><subject>Lipids</subject><subject>Lipoproteins</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Liver transplantation</subject><subject>Liver transplants</subject><subject>Metabolic disorders</subject><subject>Risk factors</subject><issn>1527-6465</issn><issn>1527-6473</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kE1Lw0AQhhdRbK2Cv0ACXryk7kc2yXor9atQ8VIvXsImmbVbNh_uJkr_vVtbKwheZgbmmYfhReic4DHBmF6bbkxjHIsDNCScJmEcJexwP8d8gE6cW2FMCBf4GA0YS1kSJ3iIXifdEmzzBrUugtu1M7rVJVRaBhPVgQ3m-sPXhZW1a42sO9nppr4JnqBYylq7ygWyLoOp0f5emmBWtcYPG8idoiMljYOzXR-hl_u7xfQxnD8_zKaTeViwSIhQKcBKlHnJJAVMVSxYJCPJhcQlp5IojikFlkdKFCkpBEAhUuX3pGS5THM2Qldbb2ub9x5cl1XaFWD8u9D0LqOcEMqSNCIevfyDrpre1v47TyU44pxw_CssbOOcBZW1VlfSrjOCs03ememy77w9erET9nkF5R78CdgD4Rb41AbW_4qy-WIr_AIFMYlp</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Syed, Taseen</creator><creator>Siddiqui, Mohammad S.</creator><general>Wolters Kluwer Health, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202109</creationdate><title>Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications</title><author>Syed, Taseen ; Siddiqui, Mohammad S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3499-ffe0f9dbd3a2e02f6934a4a59a0d52a1f5022e3b4f9c81c9eec98fa591d3ba8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adipose tissue</topic><topic>Arteriosclerosis</topic><topic>Atherogenesis</topic><topic>Cardiovascular diseases</topic><topic>Dyslipidemia</topic><topic>Fatty liver</topic><topic>Homeostasis</topic><topic>Immunosuppression</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Lipid metabolism</topic><topic>Lipids</topic><topic>Lipoproteins</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Liver transplantation</topic><topic>Liver transplants</topic><topic>Metabolic disorders</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Syed, Taseen</creatorcontrib><creatorcontrib>Siddiqui, Mohammad S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Liver transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Syed, Taseen</au><au>Siddiqui, Mohammad S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications</atitle><jtitle>Liver transplantation</jtitle><addtitle>Liver Transpl</addtitle><date>2021-09</date><risdate>2021</risdate><volume>27</volume><issue>9</issue><spage>1326</spage><epage>1333</epage><pages>1326-1333</pages><issn>1527-6465</issn><eissn>1527-6473</eissn><abstract>Cardiovascular disease (CVD), particularly atherosclerosis‐associated CVD, is a major cause of long‐term mortality after liver transplantation (LT). The liver is central in lipid homeostasis, and changes associated with insulin resistance, weight gain, adipose tissue inflammation, and development of nonalcoholic fatty liver disease (NAFLD) after LT promote atherogenesis. These factors synergistically alter lipid homeostasis, thereby leading to the production of proatherogenic lipoproteins, which contribute to the heighted risk of CVD‐associated events observed in LT recipients. Although the exact mechanism promoting this shift of a proatherogenic lipoprotein profile is currently not known, the choice of immunosuppression and preexisting metabolic risk factors (ie, NAFLD) are likely contributors. This shift in proatherogenic lipoprotein subparticles presents clinical challenges as the traditional lipid profile employed in clinical practice may not fully capture this atherogenic risk. This review focuses on lipoprotein metabolism and atherogenesis in LT recipients.
https://wileyhealthlearning.com/#/online-courses/ddb74a8d-493b-4e33-b8cc-820c79cff7cc</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>33837670</pmid><doi>10.1002/lt.26069</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-6465 |
| ispartof | Liver transplantation, 2021-09, Vol.27 (9), p.1326-1333 |
| issn | 1527-6465 1527-6473 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2511237841 |
| source | Access via Wiley Online Library; Alma/SFX Local Collection |
| subjects | Adipose tissue Arteriosclerosis Atherogenesis Cardiovascular diseases Dyslipidemia Fatty liver Homeostasis Immunosuppression Insulin Insulin resistance Lipid metabolism Lipids Lipoproteins Liver Liver diseases Liver transplantation Liver transplants Metabolic disorders Risk factors |
| title | Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A02%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atherogenic%20Dyslipidemia%20After%20Liver%20Transplantation:%20Mechanisms%20and%20Clinical%20Implications&rft.jtitle=Liver%20transplantation&rft.au=Syed,%20Taseen&rft.date=2021-09&rft.volume=27&rft.issue=9&rft.spage=1326&rft.epage=1333&rft.pages=1326-1333&rft.issn=1527-6465&rft.eissn=1527-6473&rft_id=info:doi/10.1002/lt.26069&rft_dat=%3Cproquest_cross%3E2511237841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2570455150&rft_id=info:pmid/33837670&rfr_iscdi=true |